Ribupatide (KAI-9531) Injectable

About Kailera Therapeutics

Kailera Therapeutics is a private, pre-revenue biotech company positioning itself as a next-generation contender in the rapidly expanding obesity pharmacotherapy market. With a leadership team of seasoned biopharma veterans, including CEO Ron Renaud, the company is progressing four clinical-stage assets, headlined by ribupatide (KAI-9531), a GLP-1/GIP dual agonist now in a global Phase 3 program. Its strategy leverages a strategic collaboration with Hengrui Pharma for pipeline access and clinical data, aiming to deliver differentiated treatment options through varied mechanisms of action and routes of administration to serve a broad patient population.

Therapeutic Areas

Other Obesity / Chronic Weight Management Drugs